Charles McWherter

Track

Insider profile

Currently holds a position at Cymabay Therapeutics Inc

Performance

Overall performance
2.7
Performance over holding periods
2.7
30 days 90 days 120 days
Average return 35% 8.2% 15.1%
Success rate 56% 68% 82%
Transactions
3 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Senior Vice President, Chief Scientific Officer Cymabay Therapeutics Inc None -
Charles McWherter's trades of 89Bio Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-23 2025-01-22
US 89Bio Inc (ETNB)
B Purchase
75,531 +3.4%
126.53
US$2,394,663 		75,531 +3.4% 126.53 US$2,394,663
2025-01-23 2025-01-21
US 89Bio Inc (ETNB)
B Purchase
86,985 -23.6%
68.52
US$239,065 		86,985 -23.6% 68.52 US$239,065
2024-12-09 2024-12-05
US 89Bio Inc (ETNB)
B Purchase
28,625 +16.2%
285.67
US$2,696,487 		28,625 +16.2% 285.67 US$2,696,487
2024-01-22 2024-01-19
PlS Planned sale
3,125 -17.2%
23.68
US$73,988 		3,125 -17.2% 23.68 US$73,988
2024-01-22 2024-01-19
PlS Planned sale
8,334 -35.7%
23.68
US$197,316 		8,334 -35.7% 23.68 US$197,316
2024-01-22 2024-01-19
PlS Planned sale
1,916 -11.3%
23.66
US$45,340 		1,916 -11.3% 23.66 US$45,340
2024-01-22 2024-01-19
PlS Planned sale
2,778 -15.6%
23.66
US$65,739 		2,778 -15.6% 23.66 US$65,739
2024-01-22 2024-01-19
PlS Planned sale
2,250 -13.0%
23.67
US$53,262 		2,250 -13.0% 23.67 US$53,262
2024-01-19 2024-01-19
PrS Proposed sale
18,403
23.67
US$435,645 		18,403 23.67 US$435,645
2023-12-18 2023-12-18
PrS Proposed sale
11,332
21.48
US$243,440 		11,332 21.48 US$243,440
2023-12-18 2023-12-18
PlS Planned sale
6,504 -30.2%
21.48
US$139,703 		6,504 -30.2% 21.48 US$139,703
2023-12-18 2023-12-18
PlS Planned sale
4,828 -24.3%
21.49
US$103,738 		4,828 -24.3% 21.49 US$103,738
2023-11-17 2023-11-17
PrS Proposed sale
11,342
18.28
US$207,293 		11,342 18.28 US$207,293
2023-11-17 2023-11-17
PlS Planned sale
11,342 -43.1%
18.28
US$207,293 		11,342 -43.1% 18.28 US$207,293
2023-10-18 2023-10-18
PrS Proposed sale
21,743
14.07
US$305,939 		21,743 14.07 US$305,939
2023-10-18 2023-10-18
PlS Planned sale
21,743 -59.2%
14.07
US$305,941 		21,743 -59.2% 14.07 US$305,941
2023-09-19 2023-09-18
PlS Planned sale
21,746 -59.2%
16.22
US$352,733 		21,746 -59.2% 16.22 US$352,733
2023-09-18 2023-09-18
PrS Proposed sale
21,746
16.22
US$352,731 		21,746 16.22 US$352,731
2023-08-18 2023-08-18
PrS Proposed sale
21,746
11.47
US$249,359 		21,746 11.47 US$249,359
2023-08-18 2023-08-18
PlS Planned sale
21,746 -59.2%
11.47
US$249,359 		21,746 -59.2% 11.47 US$249,359
2023-07-19 2023-07-18
PlS Planned sale
21,749 -59.2%
11.43
US$248,519 		21,749 -59.2% 11.43 US$248,519
2023-07-18 2023-07-18
PrS Proposed sale
21,749
11.43
US$248,517 		21,749 11.43 US$248,517
2023-06-21 2023-06-20
PlS Planned sale
21,749 -59.2%
8.16
US$177,383 		21,749 -59.2% 8.16 US$177,383
2023-06-20 2023-06-20
PrS Proposed sale
21,749
8.16
US$177,383 		21,749 8.16 US$177,383
2023-05-19 2023-05-18
PlS Planned sale
21,749 -59.2%
9.08
US$197,387 		21,749 -59.2% 9.08 US$197,387
2023-05-18 2023-05-18
PrS Proposed sale
21,749
9.08
US$197,385 		21,749 9.08 US$197,385